[1]
|
Day, M. (2020) Covid-19: Four Fifths of Cases Are Asymptomatic, China Figures Indicate. BMJ, 369, Article No. 1375. https://doi.org/10.1136/bmj.m1375
|
[2]
|
Sutton, D., Fuchs, K., D’Alton, M. and Gofman, D. (2020) Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. The New England Journal of Medicine, 382, 2163-2164. https://doi.org/10.1056/NEJMc2009316
|
[3]
|
Mizumoto, K., Kagaya, K., Zarebski, A. and Chowell, G. (2020) Estimating the Asymptomatic Proportion of Coronavirus Disease 2019 (COVID-19) Cases on Board the Diamond Princess Cruise Ship, Yokohama, Japan, 2020. Eurosurveillance, 25, Article 2000180. https://doi.org/10.2807/1560-7917.ES.2020.25.10.2000180
|
[4]
|
Yang, Y., Chawla, A., Zhang, J., Esa, A., Jang, H.L. and Khademhosseini, A. (2019) Applications of Nanotechnology for Regenerative Medicine; Healing Tissues at the Nanoscale. In: Atala, A., et al., Eds., Principles of Regenerative Medicine, Elsevier, Amsterdam, 485-504. https://doi.org/10.1016/B978-0-12-809880-6.00029-1
|
[5]
|
Lin, L.C.W., Chattopadhyay, S., Lin, J.C. and Hu, C.M.J. (2018) Advances and Opportunities in Nanoparticle-and Nanomaterial-Based Vaccines against Bacterial Infections. Advanced Healthcare Materials, 7, Article 1701395. https://doi.org/10.1002/adhm.201701395
|
[6]
|
Cojocaru, F.-D., Botezat, D., Gardikiotis, I., Uritu, C.-M., Dodi, G., Trandafir, L., Rezus, C., Rezus, E., Tamba, B.-I. and Mihai, C.-T. (2020) Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers. Pharmaceutics, 12, Article 171. https://doi.org/10.3390/pharmaceutics12020171
|
[7]
|
Nasrollahzadeh, M., Sajjadi, M., Soufi, G.J., Iravani, S. and Varma, R.S. (2020) Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses. Nanomaterials, 10, Article 1072. https://doi.org/10.3390/nano10061072
|
[8]
|
Akbarzadeh, A., Kafshdooz, L., Razban, Z.., et al. (2018) An Overview Application of Silver Nanoparticles in Inhibition of Herpes Simplex Virus. Artificial Cells, Nanomedicine, and Biotechnology, 46, 263-267. https://doi.org/10.1080/21691401.2017.1307208
|
[9]
|
Weiss, C., Carriere, M., Fusco, L., Capua, I., Regla-Nava, J.A., et al. (2020) Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. ACS Nano, 14, 6383-6406. https://doi.org/10.1021/acsnano.0c03697
|
[10]
|
Tavakol, S., Hoveizi, E., Kharrazi, S., Tavakol, B., Karimi, S. and Rezayat, S.M. (2017) Organelles and Chromatin Fragmentation of Human Umbilical Vein Endothelial Cell Influence by the Effects of Zeta Potential and Size of Silver Nanoparticles in Different Manners. Artificial Cells, Nanomedicine, and Biotechnology, 45, 817-823. https://doi.org/10.1080/21691401.2016.1178132
|
[11]
|
Lisuzzo, L., Cavallaro, G., Parisi, F., Milioto, S., Fakhrullin, R. and Lazzara, G. (2019) Core/Shell Gel Beads with Embedded Halloysite Nanotubes for Controlled Drug Release. Coatings, 9, Article 70. https://doi.org/10.3390/coatings9020070
|
[12]
|
Cagno, V., Andreozzi, P., D’Alicarnasso, M., Silva, P.J., Mueller, M., Galloux, M., et al. (2018) Broad-Spectrum Non-Toxic Antiviral Nanoparticles with a Virucidal Inhibition Mechanism. Nature Materials, 17, 195-203. https://doi.org/10.1038/nmat5053
|
[13]
|
Diao, B., Wang, C., Wang, R., Feng, Z., Zhang, J., Yang, H., Tan, Y., Wang, H., Wang, C., Liu, L., Liu, Y., Liu, Y., Wang, G., Yuan, Z., Hou, X., Ren, L., Wu, Y. and Chen, Y. (2021) Human Kidney Is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Nature Communications, 12, Article No. 2506. https://doi.org/10.1038/s41467-021-22781-1
|
[14]
|
Seredych, M., Haines, B., Sokolova, V., Cheung, P., Meng, F., Stone, L., et al. (2018) Graphene-Based Materials for the Fast Removal of Cytokines from Blood Plasma. ACS Applied Bio Materials, 1, 436-443. https://doi.org/10.1021/acsabm.8b00151
|
[15]
|
Tavakol, S., Ashrafizadeh, M., Deng, S., Azarian, M., Abdoli, A., Motavaf, M., et al. (2019) Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems. Biomolecules, 9, Article 530. https://doi.org/10.3390/biom9100530
|
[16]
|
Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S. and Archambault, D. (2019) Nanoparticle-Based Vaccines against Respiratory Viruses. Frontiers in Immunology, 10, Article 22. https://doi.org/10.3389/fimmu.2019.00022
|
[17]
|
Zheng, Z., Li, Z., Xu, C., Guo, B. and Guo, P. (2019) Folate-Displaying Exosome Mediated Cytosolic Delivery of siRNA Avoiding Endosome Trapping. Journal of Controlled Release, 311, 43-49. https://doi.org/10.1016/j.jconrel.2019.08.021
|
[18]
|
Arbuthnot, P. (2015) Gene Therapy for Respiratory Viral Infections. In: Gene Therapy for Viral Infections, Academic Press, Cambridge, MA, 281-297. https://doi.org/10.1016/B978-0-12-410518-8.00009-0
|
[19]
|
Rabaan, A.A., Al-Ahmed, S.H., Haque, S., Sah, R., Tiwari, R., Malik, Y.S., et al. (2020) SARS-CoV-2, SARS-CoV, and MERS-COV: A Comparative Overview. Le Infezioni in Medicina, 28, 174-184.
|
[20]
|
Gu, S.H., Yu, C.H., Song, Y., Kim, N.Y., Sim, E., Choi, J.Y., et al. (2020) A Small Interfering RNA Lead Targeting RNA-Dependent RNA-Polymerase Effectively Inhibit the SARS-CoV-2 Infection in Golden Syrian Hamster and Rhesus Macaque. bioRxiv. https://doi.org/10.1101/2020.07.07.190967
|
[21]
|
Sohail, M.F., Hussain, S.Z., Saeed, H., Javed, I., Sarwar, H.S., Nadhman, A., et al. (2018) Polymeric Nanocapsules Embedded with Ultra-Small Silver Nanoclusters for Synergistic Pharmacology and Improved Oral Delivery of Docetaxel. Scientific Reports, 8, Article No. 13304. https://doi.org/10.1038/s41598-018-30749-3
|
[22]
|
Chen, C.-K., Huang, P.-K., Law, W.-C., Chu, C.-H., Chen, N.-T. and Lo, L.-W. (2020) Biodegradable Polymers for Gene-Delivery Applications. International Journal of Nanomedicine, 15, 2131-2150. https://doi.org/10.2147/IJN.S222419
|
[23]
|
(2020) BioNTech and Pfizer Announce Regulatory Approval from German Authority Paul-Ehrlich-Institute to Commence First Clinical Trial of COVID-19 Vaccine Candidates. BIONTECH. https://investors.biontech.de/news-releases/news-release-details/biontech-and-pfizer-announce-regulatory-approval-german
|
[24]
|
Zeng, C., et al. (2020) Leveraging MRNAs Sequences to Express SARS-CoV-2 Antigens in Vivo. bioRxiv. https://www.biorxiv.org/content/10.1101/2020.04.01.019877v1 https://doi.org/10.1101/2020.04.01.019877
|
[25]
|
(2020) Arcturus Terapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine Using STARR™ Technology. ARCTURUS Therapeutics. https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-and-duke-nus-medical-school-partner
|
[26]
|
Lim, M., et al. (2020) Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies. Pharmaceutics, 12, Article 30. https://doi.org/10.3390/pharmaceutics12010030
|
[27]
|
Wang, Q., et al. (2016) Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-Human Primates. ACS Infectious Diseases, 2, 361-376. https://doi.org/10.1021/acsinfecdis.6b00006
|
[28]
|
Quinlan, B.D., et al. (2020) The SARS-CoV-2 Receptor-Binding Domain Elicits a Potent Neutralizing Response without Antibody-Dependent Enhancement. bioRxiv. https://www.biorxiv.org/content/10.1101/2020.04.10.036418v1 https://doi.org/10.1101/2020.04.10.036418
|
[29]
|
Chen, W.H., et al. (2017) Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), A SARS Vaccine Candidate. Journal of Pharmaceutical Sciences, 106, 1961-1970. https://doi.org/10.1016/j.xphs.2017.04.037
|
[30]
|
Iwasaki, A. and Yang, Y. (2020) The Potential Danger of Suboptimal Antibody Responses in COVID-19. Nature Reviews Immunology, 20, 339-341. https://doi.org/10.1038/s41577-020-0321-6
|
[31]
|
Peeples, L. (2020) News Feature: Avoiding Pitfalls in the Pursuit of a COVID-19 Vaccin. Proceedings of the National Academy of Sciences of the United States of America, 117, 8218-8221. https://doi.org/10.1073/pnas.2005456117
|
[32]
|
Zhao, J., et al. (2020) Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. Clinical Infectious Diseases, 71, 2027-2034.
|
[33]
|
Zhang, B., et al. (2020) Immune Phenotyping Based on Neutrophil-to-Lymphocyte Ratio and IgG Predicts Disease Severity and Outcome for Patients with COVID-19. medRxiv. https://www.medrxiv.org/content/10.1101/2020.03.1 2.20035048v1 https://doi.org/10.3389/fmolb.2020.00157
|
[34]
|
McCurry-Schmidt, M. (2020) LJI Scientists Awarded New Funding to COMBAT COVID-19. La Jolla Institute for Immunology. La Jolla Institute for Immunology. https://www.lji.org/news-events/news/post/lji-scientists-awarded-new-funding-to-combat-covid-19
|
[35]
|
Li, W., Joshi, M.D., Singhania, S., Ramsey, K.H. and Murthy, A.K. (2014) Peptide Vaccine: Progress and Challenges. Vaccines, 2, 515-536. https://doi.org/10.3390/vaccines2030515
|
[36]
|
Mohsen, M.O., Zha, L., Cabral-Miranda, G. and Bachmann, M.F. (2017) Major Findings and Recent Advances in Virus-Like Particle (VLP)-Based Vaccines. Seminars in Immunology, 34, 123-132. https://doi.org/10.1016/j.smim.2017.08.014
|
[37]
|
Bezu, L., et al. (2018) Trial Watch: Peptide-Based Vaccines in Anticancer Therapy. Oncoimmunology, 7, e1511506. https://doi.org/10.1080/2162402X.2018.1511506
|
[38]
|
Wang, W., et al. (2020) Dual-Targeting Nanoparticle Vaccine Elicits a Therapeutic Antibody Response against Chronic Hepatitis B. Nature Nanotechnology, 15, 406-416. https://doi.org/10.1038/s41565-020-0648-y
|
[39]
|
Shin, M.D., Shukla, S., Chung, Y.H., et al. (2020) COVID-19 Vaccine Development and a Potential Nanomaterial Path forward. Nature Nanotechnology, 15, 646-655. https://doi.org/10.1038/s41565-020-0737-y
|
[40]
|
Liu, Z., et al. (2017) Coordinating Antigen Cytosolic Delivery and Danger Signaling to Program Potent Cross-Priming by Micelle-Based Nanovaccine. Cell Discovery, 3, Article No. 17007. https://doi.org/10.1038/celldisc.2017.7
|
[41]
|
Totura, A.L. and Baric, R.S. (2012) SARS Coronavirus Pathogenesis: Host Innate Immune Responses and Viral Antagonism of Interferon. Current Opinion in Virology, 2, 264-275. https://doi.org/10.1016/j.coviro.2012.04.004
|
[42]
|
Cervantes-Barragan, L., Züst, R., Weber, F., Spiegel, M., Lang, K. S., Akira, S., Thiel, V. and Ludewig, B. (2007) Control of Coronavirus Infection through Plasmacytoid Dendritic-Cell-Derived Type I Interferon. Blood, 109, 1131-1137. https://doi.org/10.1182/blood-2006-05-023770
|
[43]
|
Davidson, S., Maini, M.K. and Wack, A. (2015) Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections. Journal of Interferon & Cytokine Research, 35, 252-264. https://doi.org/10.1089/jir.2014.0227
|
[44]
|
Newton, A.H., Cardani, A. and Braciale, T.J. (2016) The Host Immune Response in Respiratory Virus Infection: Balancing Virus Clearance and Immunopathology. Seminars in Immunopathology, 38, 471-482. https://doi.org/10.1007/s00281-016-0558-0
|
[45]
|
Keam, S., Megawati, D., Patel, S.K., Tiwari, R., Dhama, K. and Harapan, H. (2020) Immunopathology and Immunotherapeutic Strategies in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Reviews in Medical Virology, 30, e2123. https://doi.org/10.1002/rmv.2123
|
[46]
|
Kikkert, M. (2020) Innate Immune Evasion by Human Respiratory RNA Viruses. Journal of Innate Immunity, 12, 4-20. https://doi.org/10.1159/000503030
|
[47]
|
Li, X., Geng, M., Peng, Y., Meng, L. and Lu, S. (2020) Molecular Immune Pathogenesis and Diagnosis of COVID-19. Journal of Pharmaceutical Analysis, 10, 102-108. https://doi.org/10.1016/j.jpha.2020.03.001
|
[48]
|
Dhama, K., Sharun, K., Tiwari, R., Dadar, M., Malik, Y.S., Singh, K.P. and Chaicumpa, W. (2020) COVID-19, An Emerging Coronavirus Infection: Advances and Prospects in Designing and Developing Vaccines, Immunotherapeutics, and Therapeutics. Human Vaccines & Immunotherapeutics, 16, 1232-1238. https://doi.org/10.1080/21645515.2020.1735227
|
[49]
|
Casadevall, A. and Pirofski, L. (2020) The Convalescent Sera Option for Containing COVID-19. Journal of Clinical Investigation, 130, 1545-1548. https://doi.org/10.1172/JCI138003
|
[50]
|
Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., et al. (7821) Potent Neutralizing Antibodies against Multiple Epitopes on SARS-CoV-2 Spike. Nature, 584, 450-456. https://doi.org/10.1038/s41586-020-2571-7
|
[51]
|
Wec, A.Z., Wrapp, D., Herbert, A.S., Maurer, D.P., Haslwanter, D., Sakharkar, M., et al. (2020) Broad Neutralization of SARS-Related Viruses by Human Monoclonal Antibodies. Science, 369, 731-736. https://doi.org/10.1126/science.abc7424
|
[52]
|
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J.C., et al. (2020) Escape from Neutralizing Antibodies by SARSCoV-2 Spike Protein Variants. eLife, 9, e61312. https://doi.org/10.7554/eLife.61312
|
[53]
|
Felgenhauer, U., Schoen, A., Gad, H.H., Hartmann, R., Schaubmar, A.R., Failing, K., Drosten, C. and Weber, F. (2020) Inhibition of SARS-CoV-2 by Type I and Type III Interferons. Journal of Biological Chemistry, 295, 13958-13964. https://doi.org/10.1074/jbc.AC120.013788
|
[54]
|
Falzarano, D., De Wit, E., Martellaro, C., Callison, J., Munster, V.J. and Feldmann, H. (2013) Inhibition of Novel β Coronavirus Replication by a Combination of Interferon-α2b and Ribavirin. Scientific Reports, 3, Article No. 1686. https://doi.org/10.1038/srep01686
|
[55]
|
Zielecki, F., Weber, M., Eickmann, M., Spiegelberg, L., Zaki, A.M., Matrosovich, M., Becker, S. and Weber, F. (2013) Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 87, 5300-5304. https://doi.org/10.1128/JVI.03496-12
|
[56]
|
Anders, K.L., Indriani, C., Ahmad, R.A., Tantowijoyo, W., Arguni, E., Andari, B., Jewell, N.P., et al. (2018) The AWED Trial (Applying Wolbachia to Eliminate Dengue) to Assess the Efficacy of Wolbachia-Infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia: Study Protocol for a Cluster Randomised Controlled Trial. Trials, 19, Article No. 302. https://doi.org/10.1186/s13063-018-2670-z
|
[57]
|
Wang, Z., Yang, B., Li, Q., Wen, L. and Zhang, R. (2020) Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clinical Infectious Diseases, 71, 769-777. https://doi.org/10.1093/cid/ciaa272
|
[58]
|
Jodele, S. and Köhl, J. (2020) Tackling COVID-19 Infection through Complement-Targeted Immunotherapy. British Journal of Pharmacology, 178, 2832-2848. https://doi.org/10.22541/au.158880110.01220133
|
[59]
|
Zhang, Q., Wang, Y., Qi, C., Shen, L. and Li, J. (2020) Clinical Trial Analysis of 2019-nCoV Therapy Registered in China. Journal of Medical Virology, 92, 540-545. https://doi.org/10.1002/jmv.25733
|
[60]
|
Levine, M.M. (2019) Monoclonal Antibody Therapy for Ebola Virus Disease. The New England Journal of Medicine, 381, 2365-2366. https://doi.org/10.1056/NEJMe1915350
|
[61]
|
Di Gioacchino, M., Petrarca, C., Gatta, A., Scarano, G., Farinelli, A., Della Valle, L., Lumaca, A., Del Biondo, P., Paganelli, R. and Di Giampaolo, L. (2020) Nanoparticle-Based Immunotherapy: State of the Art and Future Perspectives. Expert Review of Clinical Immunology, 16, 513-525. https://doi.org/10.1080/1744666X.2020.1762572
|
[62]
|
Shi, Y. and Lammers, T. (2019) Combining Nanomedicine and Immunotherapy. Accounts of Chemical Research, 52, 1543-1554. https://doi.org/10.1021/acs.accounts.9b00148
|
[63]
|
Irvine, D.J., Hanson, M.C., Rakhra, K. and Tokatlian, T. (2015) Synthetic Nanoparticles for Vaccines and Immunotherapy. Chemical Reviews, 115, 11109-11146. https://doi.org/10.1021/acs.chemrev.5b00109
|
[64]
|
Moyer, T.J., Zmolek, A.C. and Irvine, D.J. (2016) Beyond Antigens and Adjuvants: Formulating Future Vaccines. Journal of Clinical Investigation, 126, 799-808. https://doi.org/10.1172/JCI81083
|
[65]
|
Mostafavi, M., Alizadeh, M., Shaabani, M. and Asadi, H. (2021) Metallic Nanomaterials in Cancer Theranostics: A Review of Iron Oxide and Gold-Based Nanomaterials. Journal of Nanotechnology & Material Science, 3, 564.
|
[66]
|
Kim, S.-H. and Jang, Y.-S. (2017) The Development of Mucosal Vaccines for Both Mucosal and Systemic Immune Induction and the Roles Played by Adjuvants. Clinical and Experimental Vaccine Research, 6, 15-21. https://doi.org/10.7774/cevr.2017.6.1.15
|
[67]
|
Liu, M.A. (2019) A Comparison of Plasmid DNA and MRNA as Vaccine Technologies. Vaccines, 7, Article 37. https://doi.org/10.3390/vaccines7020037
|
[68]
|
Afrough, B., Dowall, S. and Hewson, R. (2019) Emerging Viruses and Current Strategies for Vaccine Intervention. Clinical and Experimental Immunology, 196, 157-166. https://doi.org/10.1111/cei.13295
|
[69]
|
Zaman, M., Good, M.F. and Toth, I. (2013) Nanovaccines and Their Mode of Action. Methods, 60, 226-231. https://doi.org/10.1016/j.ymeth.2013.04.014
|
[70]
|
Ghanavi, J., Mostafavi, M. and Ghanavi, Z. (2016) Method for the Synthesis of Metallic Nano Products. United States Patent No. US 9,487,399.
|
[71]
|
Jalaledin, G. and Mehrnaz, M. (2011) Method for Producing Rod-Shaped and Branched Metallic Nano-Structures by Polyol Compounds. United States Patent Application No. US 12/870,792.
|
[72]
|
Savareh, A., Bashiri, B.A. and Mostafavi, M. (2017) Neighborhood Matrix: A New Idea in Matching of Two Dimensional Gel Images. Progress in Biological Sciences, 6, 129-137.
|
[73]
|
Mostafavi, M., Alizadeh, M., Shaabani, M. and Ahad Baqeri, S. (2018) Engineering Plasmonic Nanostructures with Combining Ultrasound and Laser Pulses. Health Biotechnology and Biopharma, 2, 49-55.
|
[74]
|
Mostafavi, M. and Ghanavi, J. (2012) Nanotechnology in Proteomics: Current Status, Promises and Challenges. Journal of Paramedical Sciences, 3.
|
[75]
|
Mostafavi, M., Ghanavi, J., Shaabani, M., Asadi, H. and Alizadeh, M. (2021) Application of Semiconductor Nanomaterials in Cancer Theranostics. Journal of Nanomedicine & Nanotechnology, 12, Article No. 563. https://www.walshmedicalmedia.com/open-access/application-of-semiconductor-nanomaterials-in-cancer-theranostics.pdf
|